The use of human papillomavirus seroepidemiology to inform vaccine policy
- PMID: 19773679
- PMCID: PMC4237610
- DOI: 10.1097/OLQ.0b013e3181bce102
The use of human papillomavirus seroepidemiology to inform vaccine policy
Comment on
-
HPV 6/11, 16, 18 seroprevalence in men in two US cities.Sex Transm Dis. 2009 Nov;36(11):671-4. doi: 10.1097/OLQ.0b013e3181bc094b. Sex Transm Dis. 2009. PMID: 19809385
References
-
- Dunne EF, Nielson CM, Hagensee ME, Papenfuss MR, Harris RB, Herrel N, et al. HPV 6/11, 16, 18 seroprevalence in men in two U.S. cities. Sex Transm Dis. 20092009 Ref Type: Journal (Full) - PubMed
-
- Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):324–7. - PubMed
-
- Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007 Sep 8;370(9590):890–907. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
